



The Gilead UK & Ireland Fellowship Programme
Gilead Sciences Ltd
Granta Park
Abington
Cambridge
CB21 6GT

10th December 2009

To whom it may concern

Subject: The Gilead UK & Ireland Fellowship Programme 2010

Following the successful launch of the Gilead UK and Ireland Fellowship Programme (GUKIFP) in 2009, we are pleased to provide details for an expanded Fellowship Programme for 2010, which aims to provide grants amounting to £780,000.

In 2009 the Fellowship review committee awarded 19 grants totalling over £335,000 across three disease areas – HIV, Invasive Fungal Disease and Chronic Hepatitis B (cHBV) to applicants throughout the UK and Ireland whose projects represented a broad range of initiatives in a variety of settings from Aberdeen to Dorset.

The committee were genuinely impressed by the diversity and coverage of projects submitted for funding in 2009 and subsequently, the lessons learnt from the successful applications will be shared at a Best Practice Sharing Event to be held at The Kings Fund in London on 20th and 21st May 2010. Further details of this event can be obtained by contacting the Fellowship co-ordinator at fellowshipprogramme@gilead.com.

The aims of this programme are to support the development, exploration and dissemination of best practice which enhances patient care in the specific disease areas of HIV, Invasive Fungal Disease and Chronic Hepatitis B. Financial grants amounting up to £780,000 will be awarded to individual organisations or groups of healthcare providers within a locality whose proposals best demonstrate a plan to deliver:

1. Targeted, locally based initiatives, in high prevalence areas that increase HIV diagnosis and linkage into care.

£300,000 will be available and this is expected to fund 10-14 projects

2. Broader, regional based initiatives which aim to replicate proven and effective, HIV diagnosis programmes across a clinical network by utilising existing linkages to care.

£300,000 will be awarded to 3 to 4 projects. These grants will be awarded at SHA/Clinical network level and are contingent upon committed matched funding from the local NHS, to ensure sustainability of the project

3. Targeted, locally based initiatives, in high prevalence areas, that increase cHBV diagnosis and linkage into care.

£100,000 will be available and this is expected to fund 6-8 projects

4. Audit programmes to determine the optimal treatment pathways for patients with Invasive Fungal Disease.

£80,000 will be available for and this is expected to fund 4-6 projects

Clear criteria upon which grant requests will be assessed have been established as we expect this to be a highly competitive process for funding, similar to 2009.

Applications will be accepted from 10th December 2009 – 31st March 2010 and we anticipate awards being made by the end of April 2010. The funding awarded is contingent on projects being completed by March 2011. For regional based HIV testing initiatives we would expect the Gilead funding to be utilised within 12 months from the award date, even if the project continues beyond that date with local NHS funding.

In order to facilitate the sharing of best practice, Gilead Sciences Ltd will again be hosting an event in the second quarter of 2011 at which the award recipients will be invited to present the learnings gained from their project with other grant recipients and interested colleagues.

Gilead is committed to supporting local initiatives which ultimately improve patient care and we look forward to receiving completed applications over the next few months. For more information on The Gilead UK & Ireland Fellowship Programme, for details of how to apply and the assessment criteria, please contact us at fellowshipprogramme@gilead.com.

Yours sincerely,



Lisa Bright
General Manager
Gilead Sciences Ltd, UK and Ireland



Dr Cham Herath
Medical Director
Gilead Sciences Ltd, UK and Ireland